Abstract

The HAS recommends integrating the Nuvaxovid vaccine into the booster vaccination strategy against Covid-19 as an alternative to bivalent mRNA vaccines only in subjects who no longer wish or can no longer receive an mRNA vaccine. HAS recommends that the current booster campaign be carried out preferentially with a bivalent mRNA vaccine (Spikevax bivalent Original/Omicron BA.1, Comirnaty bivalent Original/Omicron BA.1, Comirnaty bivalent Original/Omicron BA.4-5, Spikevax bivalent Original/Omicron BA.4-5), regardless of the vaccine(s) previously used.

  • Recommendation
  • Europe
  • France
  • COVID-19